Teva launches 1st generic of Absorica

Teva Pharmaceuticals is adding to its generics lineup with the first generic of severe acne treatment Absorica (isotretinoin). The company will be offering the product in 10-, 20-, 25-, 30- and 40-mg dosage strengths. 

"Teva’s first-to-market generic version of Absorica (isotretinoin) capsules in the U.S. is an important treatment option for patients living with severe recalcitrant nodular acne, and who are unresponsive to conventional acne therapy, including antibiotics," said Christine Baeder, senior vice president and COO of U.S. generics at Teva USA. "With more than 30 dermatological products in Teva’s generics portfolio, we are proud to add another accessible option for patients."

Teva’s isotretinoin capsules are indicated to treat sever recalcitrant nodular acne in non-pregnant patients 12 years old and older with multiple inflammatory nodules that are 5 mm in diameter or greater. 

The product had annual U.S. sales of more than $158 million for the year ended February 2021, according to IQVIA data.